Prestige Consumer Healthcare (PBH) Cash from Investing Activities (QoQ) (2010 - 2025)
Prestige Consumer Healthcare (PBH) Cash from Investing Activities (QoQ) (2010 - 2025) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.38 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,289.21% |
| Sep 30, 2025 | -51.14% |
| Jun 30, 2025 | 44.29% |
| Mar 31, 2025 | 64.56% |
| Dec 31, 2024 | -384.26% |
| Sep 30, 2024 | 4.84% |
| Jun 30, 2024 | 85.80% |
| Mar 31, 2024 | -233.72% |
| Dec 31, 2023 | -53.24% |
| Sep 30, 2023 | -226.30% |
| Jun 30, 2023 | 136.54% |
| Mar 31, 2023 | -252.63% |
| Dec 31, 2022 | 24.12% |
| Sep 30, 2022 | -126.93% |
| Jun 30, 2022 | 68.21% |
| Mar 31, 2022 | 83.72% |
| Dec 31, 2021 | 91.27% |
| Sep 30, 2021 | -17,410.66% |
| Jun 30, 2021 | 72.98% |
| Mar 31, 2021 | 14.53% |